1. Academic Validation
  2. Identification of small-molecule inhibitors of the colorectal cancer oncogene Krüppel-like factor 5 expression by ultrahigh-throughput screening

Identification of small-molecule inhibitors of the colorectal cancer oncogene Krüppel-like factor 5 expression by ultrahigh-throughput screening

  • Mol Cancer Ther. 2011 Nov;10(11):2043-51. doi: 10.1158/1535-7163.MCT-11-0550.
Agnieszka B Bialkowska 1 Melissa Crisp Thomas Bannister Yuanjun He Sarwat Chowdhury Stephan Schürer Peter Chase Timothy Spicer Franck Madoux Chenlu Tian Peter Hodder Daniel Zaharevitz Vincent W Yang
Affiliations

Affiliation

  • 1 Division of Digestive Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA. oberzyna@gmail.com
Abstract

The transcription factor Krüppel-like factor 5 (KLF5) is primarily expressed in the proliferative zone of the mammalian intestinal epithelium, where it regulates cell proliferation. Studies showed that inhibition of KLF5 expression reduces proliferation rates in human colorectal Cancer cells and intestinal tumor formation in mice. To identify chemical probes that decrease levels of KLF5, we used cell-based ultrahigh-throughput screening (uHTS) to test compounds in the public domain of NIH, the Molecular Libraries Probe Production Centers Network library. The primary screen involved luciferase assays in the DLD-1/pGL4.18hKLF5p cell line, which stably expressed a luciferase reporter driven by the human KLF5 promoter. A cytotoxicity counterscreen was done in the rat intestinal epithelial cell line, IEC-6. We identified 97 KLF5-selective compounds with EC(50) < 10 μmol/L for KLF5 inhibition and EC(50) > 10 μmol/L for IEC-6 cytotoxicity. The two most potent compounds, CIDs (PubChem Compound IDs) 439501 and 5951923, were further characterized on the basis of computational, Western blot, and cell viability analyses. Both of these compounds, and two newly synthesized structural analogs of CID 5951923, significantly reduced endogenous KLF5 protein levels and decreased viability of several colorectal Cancer cell lines without any apparent impact on IEC-6 cells. Finally, when tested in the NCI-60 panel of human Cancer cell lines, compound CID 5951923 was selectively active against colon Cancer cells. Our results show the feasibility of uHTS in identifying novel compounds that inhibit colorectal Cancer cell proliferation by targeting KLF5.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-W011044
    99.00%, KLF5 抑制剂
    KLF